Atkinson Katie
Weill Cornell Medicine.
Clin J Oncol Nurs. 2019 Apr 1;23(2):212-216. doi: 10.1188/19.CJON.212-216.
The thrombopoietin receptor agonists, eltrombopag and romiplostim, are second-line agents used to treat chronic immune thrombocytopenia purpura (ITP) in adults and children. ITP is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, petechiae, wet purpura, or blood in the urine or stool. This article reviews ITP treatment for adult and pediatric patients, including the use of the oral agent eltrombopag and the injectible agent romiplostim, nursing considerations, and patient education.
血小板生成素受体激动剂艾曲泊帕和罗米司亭是用于治疗成人及儿童慢性免疫性血小板减少性紫癜(ITP)的二线药物。ITP是一种罕见的自身免疫性疾病和血液系统疾病,其特征是血小板计数减少,可导致严重症状,如出血、瘀伤、鼻出血、瘀点、湿性紫癜或血尿或便血。本文综述了成人和儿童患者的ITP治疗,包括口服药物艾曲泊帕和注射药物罗米司亭的使用、护理注意事项及患者教育。